Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRNX
SellHot AirCrinetics Pharmaceuticals, Inc. · Healthcare · United States · $9.0B · Avg Vol: $501M/d
COMPANY DESCRIPTION
Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative oral therapeutics for rare endocrine diseases and endocrine-related tumors. The company focuses on creating convenient oral alternatives to traditional injectable treatments, with its lead candidate, paltopirdif, in advanced clinical trials for acromegaly, aiming to improve patient quality of life.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.7M | 4.0M | 1.0M | 7.7M | 17.6% | 42.2M | 161.9M | 178.6M | 381.8% |
| EPS | -3.15 | -3.69 | -3.69 | -4.95 | — | -5.05 | -4.54 | -4.01 | — |
| Shares | 53.9M | 68.2M | 92.9M | 95.6M | +77.4% | 106.1M | — | — | — |
| Debt | 3.1M | 51.7M | 51.7M | 48.5M | 150.9% | 47.2M | — | — | — |
| Equity | 316.3M | 539.1M | 1.3B | 992.1M | 46.4% | — | — | — | — |
| Op CF | -115.2M | -168.6M | -230.2M | -377.9M | — | -422.5M | — | — | — |
| Inv CF | -174.0M | -200.4M | -574.8M | 173.9M | — | — | — | — | — |
| Fin CF | 122.0M | 391.2M | 1.0B | 40.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc.(you) | $9.0B | 24 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 25 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | 21 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 26 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 31 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%